查看文章

Introduction: Patients with severe asthma frequently have other significant comorbidities. Furthermore, some asthmatics considered for biologic therapy may already be taking such medication for a non-pulmonary indication. Little, however, is known about the safety and efficacy of mepolizumab, an anti-interleukin-5 (anti-IL-5), used concurrently with other biologic drugs. This report describes a patient with severe eosinophilic asthma who was prescribed mepolizumab in addition to ixekizumab, an anti-interleukin-17 medication for psoriasis. Description: A 66-year-old woman presented to the clinic with ongoing exertional dyspnea (MRC 3), dry coughing, and wheezing. She had a longstanding history of asthma and was currently treated with mometasoneformoterol metered-dose inhaler (MDI) 200 mcg/5 mcg 2 inhalations twice daily, tiotropium soft mist inhaler 2.5 mcg 2 inhalations once daily, and salbutamol MDI …